Abstract: Described herein are small molecule cap-dependent inhibitors, including the compound of the formula: which compounds that can induce the accumulation of the p53 tumor suppressor protein in cancer cells that still express wild-type p53, as well as methods of using those compounds to, among other things, treat neuroblastoma, pediatric glioblastoma multiforme or breast cancer.

Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.

Abstract: Systems and methods for the clinical diagnosis of functional bladder states and disorders based upon contractile frequencies and variability. Systems and methods are also provided for the clinical diagnosis of functional bowel states and disorders based upon contractile frequencies and variability.

Abstract: In an embodiment, the present disclosure pertains to methods of inhibiting bacterial growth. Generally, the methods include exposing bacteria to an anti-bacterial compound as disclosed herein. In some embodiments, the exposing occurs in vivo in a subject in order to treat or prevent a bacterial infection. In additional embodiments, the present disclosure pertains to anti-bacterial compounds that are suitable for inhibiting bacterial growth.

Abstract: Described herein are methods of treating RNA virus infections with a therapeutic combination of an antiviral nucleobase compound and a de novo nucleotide biosynthesis inhibitor (DNNBi). An aspect of the invention is a method for the treatment of an RNA virus infection comprising administering a therapeutic combination as a combined formulation or by alternation to a patient, wherein the therapeutic combination comprises therapeutically effective amounts of (i) an antiviral nucleobase or a pharmaceutically acceptable salt thereof, and (ii) a de novo nucleotide biosynthesis inhibitor (DNNBi) or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are anti-OVA-serine proteinase inhibitor (ser-pin) B13 monoclonal antibodies and antigen-binding antibody fragments that selectively and specifically bind to an epitope of serpin B13, compositions con-taining these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. These antibodies and antigen-binding frag-ments thereof are useful for inhibiting serpin B13 and for treating serpin B13-related diseases, e.g., type I diabetes.

Abstract: Materials and methods for gene editing using improved targeted endonucleases and endonuclease systems (e.g., Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) endonuclease systems) are provided herein.

Abstract: A digital-to-analog converter device including a set of components, each component included in the set of components including a number of unit cells, each unit cell being associated with a unit cell size indicating manufacturing specifications of the unit cell is provided by the present disclosure. The digital-to-analog converter device further includes a plurality of switches, each switch included in the plurality of switches being coupled to a component included in the set of components, and an output electrode coupled to the plurality of switches. The digital-to-analog converter device is configured to output an output signal at the output electrode. A first unit cell size associated with a first unit cell included in the set of components is different than a second unit cell size associated with a second unit cell included in the set of components.

Abstract: The exemplary systems, methods, and interfaces may obtain and analyze electrode signals from a plurality of external electrodes. The electrode signals may include at least an anterior set of electrode signals and a posterior set of electrode signals. The anterior and posterior sets of electrode signals may be used to generate, or provide, various metrics of cardiac electrical heterogeneity and various graphical depictions that may be useful in assessing a patient's cardiac functionality.

Abstract: Described herein are methods of recellularizing an organ or tissue matrix.

Abstract: In one embodiment, the present invention is a method of treating glioma and medulloblastoma brain tumors using the Zika virus and a tumor vaccine.

Abstract: This document provides oilseed plants (e.g., pennycress plants) having increased levels of one or more saturated fatty acids, increased levels of one or more polyunsaturated fatty acids (PUFAs), altered (e.g., increased or decreased) levels of oleic acid, and/or altered (e.g., increased or decreased) levels of erucic acid. For example, oilseed plants having reduced polypeptide levels and/or reduced polypeptide activity of one or more polypeptides involved in triglyceride synthesis (e.g., diacylglycerol O-acyltransferase 1 (TAG1) can have increased levels of stearic acid, increased levels of one or more PUFAs, altered levels of oleic acid, and/or altered levels of erucic acid. Also provided herein are methods and materials for making and using oilseed plants having increased levels of one or more saturated fatty acids, increased levels of one or more PUFAs, altered levels of oleic acid, and/or altered levels of erucic acid.

Abstract: A cryopreservative composition includes a sugar component with a total concentration of sugar components in the composition of 300 mM or less; a sugar alcohol component, with a total concentration of sugar alcohol components in the composition of 2 M or less; and at least one of a polymer component and albumin, with the proviso that the composition includes less than a cryopreservative amount of dimethyl sulfoxide (DMSO). A method of cryopreserving a cell includes adding a cell to the cryopreservative composition; freezing the composition; storing the frozen composition; thawing the composition; removing the cell from the thawed composition; and culturing the cell under conditions effective for the cell to remain viable. The freezing may include cooling at a rate of 0.1° C./min to 5° C./min. The method may be performed without a washing step after thawing.

Abstract: A digital-to-analog converter device including a set of components, each component included in the set of components including a number of unit cells, each unit cell being associated with a unit cell size indicating manufacturing specifications of the unit cell is provided by the present disclosure. The digital-to-analog converter device further includes a plurality of switches, each switch included in the plurality of switches being coupled to a component included in the set of components, and an output electrode coupled to the plurality of switches. The digital-to-analog converter device is configured to output an output signal at the output electrode. A first unit cell size associated with a first unit cell included in the set of components is different than a second unit cell size associated with a second unit cell included in the set of components.

Abstract: This document provides materials and methods for generating oilseed (e.g., pennycress) plants that having low levels of erucic acid. For example, oilseed plants having reduced expression levels of one or more polypeptides involved in erucic acid metabolism (e.g., fatty acid elongase 1 (FAE1)), as well as materials and methods for making and using oilseed plants having low levels of erucic acid are provided.

Abstract: Block copolymers that include one or more galactose based blocks and one or more cationic blocks; polyplexes including disclosed block copolymers and one or more nucleic acids; and methods of delivering a nucleic acid to a cell which can include delivering a polyplex to the cell.

Abstract: A hearing system to activate an auditory system using cerebrospinal fluids includes at least one processor configured to receive an audio signal captured using a sound sensor (e.g., a microphone), extract temporal and spectral features from the audio signal, and create modulated ultrasound signals in a range of 20 Hz to 20 kHz with ultrasound carrier frequencies in the range of 50 kHz to 4 MHz, which are ultrasound frequencies that are well-suited to reach the cerebrospinal fluids (e.g., can pass across the skull/bones to reach the cerebrospinal fluids). The system further includes at least one ultrasonic transducer which receives the modulated signal and delivers the modulated signal to the body and activates the auditory system via vibration of cerebrospinal fluids that vibrate cochlear fluids, bypassing the normal conductive pathway that uses middle ear bones and minimizing bone conduction and distortion through the skull.

Abstract: This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.

Abstract: Systems and methods for gene targeting in plants, including systems and methods that include the use of geminiviruses and customizable endonucleases.

Abstract: Disclosed herein are compositions comprising a membranolytic polymer or a salt thereof and a chemotherapeutic agent or a salt thereof and compositions comprising a membranolytic polymer or a salt thereof and a shielding polymer or a salt thereof. Also disclosed are methods and uses for treating diseases such as cancer with these compositions.